Comparative oncology for tackling rare cancers

P3-0428

ARRS

 

 

General Data

 

Member of UL

Veterinary faculty

 

Name of the leading partner

University of Nova Gorica, head of the research programme group: prof. dr. Ario de Marco  

Status

partner  

Project code/ Projet No.

P3-0428  

Project Title

Comparative oncology for tackling rare cancers  

Financier

ARRS  

Project period

1.1.2022 – 31.12.2027  

Yearly sum of FTE

2.5 FTE  

Leader

prof. dr. Nataša Tozon  

Scientific field

Medicine/Biotechnics  

Partners

Institute of Oncology Ljubljana, Veterinary faculty Ljubljana

 

 

 

Project Phases

Project phases

 

Project Description

Rare cancers are responsible for almost one fourth of the total cancers in EU, have worse prognosis than common cancers and consequently their social and economic burden is extremely elevated in absolute terms. The limited number of available patients for each single disease sub-type renders difficult both the investigation of the involved biological mechanisms and the development of ad hoc effective pharmacological therapies. Also the design and test of complementary therapies is often slowed down by the absence of appropriate animal models which would recapitulate the human features. Pet dogs have been proposed as optimal animal model for oncological diseases since they develop spontaneous tumors with characteristics sufficiently similar to those of humans and are highly suitable for translational studies. Our programme aims at creating a powerful network of expertise to improve the quality of care for both, canine and human patients. Its major reference is the highly acknowledged US consortium for Comparative Oncology (https://ccr.cancer.gov/Comparative-Oncology-Program; Canine Comparative Oncology and Genomics Consortium (CCOGC) - www.ccogc.org) for which no similar counterpart exists at EU level. The three proposer groups wish to further innovate the idea by proposing a platform for the isolation of immunoreagents suitable for both diagnostic and therapy, able to recognize both canine and human antigens and to be applied to oncological diseases that are neglected by basic research and pharmaceutical development because of their rarity. The UNG group is a leading lab in ligand technology (phage display, in vitro panning, nanobodies, alternative scaffolds, antibody fragment functionalization), whereas the VLU is the absolute national reference for canine oncology and the OI group has international reputation in oncological therapy.  In this perspective, our proposal would represent an ambitious and exclusive challenge, not only at the national level, but the participant quality will render feasible the goal accomplishment.

 

Structure of the Project Group 

https://cris.cobiss.net/ecris/si/sl/project/18969